Tag: pharmaceuticals
-
Trial Shows No Benefit from GSK Chronic Heart Disease Drug
The global pharmaceutical company GlaxoSmithKline (GSK) reported today in a late-stage clinical trial its candidate drug darapladib to treat chronic coronary heart disease did not meet its goal of increasing the amount of time between severe heart problems compared to a placebo. The company says some of the trial’s secondary goals related to coronary events…
-
Simple Test Cuts Antibiotic Use Among Sore Throat Patients
Researchers at University of Southampton and other institutions in the U.K. and Australia found a simple nine-item test can help clinicians better determine if patients complaining of a sore throat need antibiotics. The team led by Southampton’s Paul Little, professor of primary care research, published its findings in a recent issue of the British Medical…
-
Research Consortium Applies X-ray Lasers to Drug Molecules
A group of eight universities and research institutes in the U.S. is advancing the use of X-ray laser technology in biology, with direct applications in finding molecular targets for new therapies. The Center for Biology with X-ray Laser, or BioXFEL, is funded by a $25 million grant from National Science Foundation, led by University at…
-
GlaxoSmithKline Names Academic Drug Discovery Partners
The pharmaceutical company GlaxoSmithKline named 10 academic scientists to its Discovery Fast Track competition that aims to turn university research findings into new therapies. The researchers will get access to GlaxoSmithKline’s facilities and materials to accelerate the drug discovery process, potentially leading to a collaboration to further develop the compound. Discovery Fast Track began in…
-
FDA Approves Leukemia Treatment, First Breakthrough Therapy
The U.S. Food and Drug Administration on Friday approved an antibody designed to treat chronic lymphocytic leukemia, when taken with chemotherapy. Obinutuzumabm — developed and marketed as the brand name Gazyva by the biotechnology company Genentech, a division of Roche in South San Francisco, California — is the first drug designated as a breakthrough therapy approved…
-
Strategy Sought to Encourage New Anticoagulant Prescriptions
A new challenge on InnoCentive is looking for new ways to encourage physicians to prescribe anticoagulant drugs other than the commonly used warfarin for decreasing the formation of blood clots in people with atrial fibrillation. The competition has a total purse of $7,500 and a deadline of 27 November 2013. InnoCentive in Waltham, Massachusetts conducts…
-
Automated System Developed to Monitor Drug-Induced Comas
Engineers at Massachusetts Institute of Technology and medical researchers at Massachusetts General Hospital in Boston developed and tested in lab animals a system connecting the brain to a drug infusion device that automatically controls anesthesia drugs administered to patients in a drug-induced coma. The team led by MIT engineering professor Emery Brown, who is also…
-
Myelin Foundation to Assess Multiple Sclerosis Treatment
Myelin Repair Foundation in Saratoga, California is collaborating with drug development company Bionure Inc. in Barcelona, Spain to evaluate Bionure’s compound BN201 as a therapy candidate for multiple sclerosis. Financial aspects of the agreement were not disclosed. Multiple sclerosis is a condition where the immune system attacks the central nervous system and damages the fatty,…
-
Novartis Licenses University Stem Cell Transplant Technology
The global pharmaceutical company Novartis, based in Switzerland, is licensing research conducted at University of Louisville to help transplant patients better tolerate donated kidneys. Financial aspects of the agreement between Novartis and the Louisville biotechnology company Regenerex LLC, the original licensee and completed last month, were not disclosed. Regenerex is the company founded by Suzanne…
-
Peptide Developed to Combat Antibiotic-Resistant Bacteria
Researchers at University of Copenhagen in Denmark and University of British Columbia in Canada developed and tested in the lab a substance they say quickly and effectively kills multiple types of bacteria, including those resistant to current antibiotics. The team led by Copenhagen’s Henrik Franzyk and UBC’s Robert Hancock published their findings last week in the…